相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Immunology
Lennard Y. W. Lee et al.
Summary: The study found that the infectivity of SARS-CoV-2 varies with case viral load, contact event type, and age. Those with high viral loads are the most infectious. The B.1.1.7 variant increases transmission by 50%. The best performing LFDs can detect most infectious cases.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.
Article
Infectious Diseases
Michael Marks et al.
Summary: The viral load of index cases is a key driver of SARS-CoV-2 transmission, while the viral load of contacts at baseline is strongly associated with the risk of developing symptomatic COVID-19 and shortening the incubation period in a dose-dependent manner.
LANCET INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Joseph A. Lewnard et al.
Summary: Observational studies on COVID-19 vaccine effectiveness face challenges such as misclassification and confounding, which should be addressed through practical strategies at both study design and analysis stages to reduce bias. Traditional case-control and test-negative design studies may encounter important threats to validity, particularly in the context of SARS-CoV-2 infection and COVID-19 natural history parameters.
Article
Biochemistry & Molecular Biology
Matan Levine-Tiefenbrun et al.
Summary: COVID-19 vaccines not only provide protection to individual vaccinees, but may also reduce viral load in breakthrough infections, potentially leading to lower infectiousness and further suppressing virus spread.
Article
Medicine, General & Internal
Jamie Lopez Bernal et al.
Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Emma Pritchard et al.
Summary: Results from the Office for National Statistics COVID-19 Infection Survey in the UK demonstrate that the ChAdOx1 nCoV-19 and BNT162b2 vaccines reduce the incidence of new SARS-CoV-2 infections by up to 65% with a single dose and up to 80% after two doses, with no significant differences in efficacy observed between the two vaccines.
Letter
Medicine, General & Internal
Ross J. Harris et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Catherine M. Brown et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Microbiology
Jia Wei et al.
Summary: A longitudinal study on 45,965 adults in the UK revealed that older individuals, especially those aged >60 years, had lower antibody levels after a single dose of ChAdOx1 or BNT162b2 COVID-19 vaccines. Prioritizing vaccine allocation for those not previously infected and older individuals for the second dose is recommended based on the findings. Further data is needed to fully understand the relationship between quantitative antibody responses and vaccine-mediated protection.
NATURE MICROBIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Xi He et al.
Article
Immunology
Wakaba Fukushima et al.
